Takeda keeps full-year guidance and lifts profit forecast on currency assumptions

what happened

Japanese drugmaker Takeda kept its full-year guidance and still expects a low-single-digit revenue decline at constant currency. According to TradingView, the company raised its revenue forecast by 60 billion yen and its core operating profit forecast by 30 billion yen, to 1.19 trillion yen, on currency assumptions.

The company said its transformation affected about 3,000 roles by September 30. Procurement cuts delivered roughly 30 billion yen in annualized savings against a target of 100 billion yen in gross savings by fiscal 2026. Restructuring costs are now estimated at about 160 billion yen.

The pipeline also moved forward. ORZEYFUL launched in Japan and China on October 15, and a U.S. launch is planned for early November, pending DEA scheduling. The FDA approved MIMRYLO, and the zasocitinib psoriasis application was accepted for priority review.

why it matters

The main signal for investors is that guidance was not cut, but part of the profit increase comes from the yen, so its durability depends on currency moves. Restructuring costs and the timing of U.S. regulatory decisions remain factors for the stock. This item is based on a TradingView AI-generated summary, which may contain inaccuracies.

market impact

Takeda shares: guidance held, but part of the profit lift comes from the yen, a mixed backdrop.

• ↔Takeda shares (TSE:4502) mixed — guidance held and raised on FX, but restructuring costs are rising

tags

instruments